Thursday 16 October, 2025
Introduction: As part of the clinical development plan, a set of in vitro studies were undertaken to determine the drug-drug…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK
Thursday 16 October, 2025
Introduction: Oral drug absorption is a complex process depending on the interplay between both compound characteristics and physiological and dynamic properties…
Read morePhysiologically based pharmacokinetic modeling and simulations to characterize the effect of cyclodextrins on the exposure of asciminib in lieu of clinical trials
Thursday 16 October, 2025
Objectives: In a clinical study, co-administration of multiple doses of an itraconazole oral solution containing hydroxypropyl-beta-cyclodextrin (HP-beta-CD) at a total…
Read moreApplication of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine.
Thursday 16 October, 2025
Objectives: Rivaroxaban (direct oral anticoagulants, CYP3A4 substrate drug) and carbamazepine (anti-epileptic drug, potent CYP3A4 inducer) could be prescribed concomitantly to…
Read morePhysiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction
Thursday 16 October, 2025
Introduction: Ruxolitinib is an orally administered small molecule multi-kinase inhibitor with potent and selective inhibition activity against janus kinase 1/2…
Read moreP-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution
Thursday 16 October, 2025
Introduction/objectives: Transporter-mediated drug-drug interactions (DDIs) are studied in intestine, liver, and kidney. However, considerations of the effect of DDIs on…
Read morePharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy
Thursday 16 October, 2025
Introduction/Objectives: PBPK are bottom-up models that integrate physiological information of the organism with the physicochemical characteristics of the drug, allowing a…
Read moreA physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice
Thursday 16 October, 2025
Introduction/Objectives: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability to selectively infect and replicate…
Read moreA physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings
Thursday 16 October, 2025
Introduction/Objectives: Colorectal cancer holds the third position among cancers affecting men and the second position among cancers affecting women, being…
Read moreApplication of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function
Thursday 16 October, 2025
Objectives: Ceftazidime injection has been used as prophylaxis for emergency caesarean section. The drug is given just before the surgery that…
Read more